Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami

Clobazam (CLB) and cenobamate (CNB) are commonly used antiseizure medications (ASMs) in the treatment of patients with drug-resistant epilepsy (DRE). However, concomitant use of these two ASMs may lead to significant treatment-related adverse events (TRAE). Furthermore, these TRAE may be exacerbated...

Descripció completa

Dades bibliogràfiques

Autors principals:	Andrew Zillgitt, David E Burdette, Atheel Yako, Revati Rashingkar, Ashleigh Terrell, Sydney Jacobs, Michael D Staudt
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-09-01
Col·lecció:	Epilepsy & Behavior Reports
Matèries:	Clobazam Cenobamate Pharmacogenetics Idiopathic generalized epilepsy Responsive neurostimulator
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589986425000590
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!